Editor’s Memo

Welcome back all. The summer of 2021 is commencing. As we all step into this new season with optimism and anticipation, it is a great time reflect back on this challenging last year. I would like to thank everyone at PHA, Allen Press, and every member of the editorial board, guest editor, author and panelist who have generously contributed their time, effort and expertise in creating outstanding issues of Advances, during a time when none of us had a lot of time. These issues have received some of the highest readerships we have seen. It is this enduring dedication by staff and faculty alike who make this unique journal so well-loved in our community. Thank you to all.

I would like to congratulate Drs. Oksana Shlobin and Anjali Vaidya, the co-guest editors of this edition of Advances. The topic is Group 5 PH, an ever changing and ever challenging topic for us all. Drs. Shlobin and Vaidya and their faculty have met the challenge of organizing this difficult group of conditions into a beautifully written resource which touches on the most important subgroups in Group 5. The group focused the round table and PHGR section on Sarcoidosis, a major topic in the 6th WSPH. Readers will turn to these documents when looking for expert viewpoints on this controversial topic.

I know you will enjoy this issue of Advances. This issue will serve as a great resource in 2021 and beyond, as this topic will continue to ebb and flow with more experience and knowledge.

Deborah Jo Levine, MD

Professor of Medicine, Pulmonary and Critical Care

Medical Director Lung Transplantation

Director of Pulmonary Hypertension

University of Texas Health Science Center, San Antonio

San Antonio, TX

Guest Editor’s Memo

Group 5 Pulmonary Hypertension (PH), i.e. the Miscellaneous Group, is a heterogeneous group that includes a myriad of conditions that differ in etiology and pathophysiology. One can argue that Group 5 PH is the most complex group in the current classification of PH, as, in addition to variability of the underlying conditions, the mechanisms of superimposed PH differ vastly, making a proper diagnosis and management more nuanced and challenging.

In this issue of Advances, we are very excited to bring to the readers an array of topics, covered by the experts in the field with particular clinical and research interests in specific forms of Group 5 PH.

Drs. Melendres-Groves and Bostwick’s article The Story of Group 5 PH offers the readers an overview of the historical context of the classification system and how Group 5 has morphed into its current classification. The paper further succinctly describes major subgroups of Group 5 PH including hematologic (chronic hemolytic anemias, myeloproliferative disorders), systemic and metabolic disorders (Pulmonary Langerhans Cell Histiocytosis, Gaucher disease, Glycogen storage disease, Neurofibromatosis, and Sarcoidosis), congenital heart diseases that do not fall into Group 1 PAH, and also covers chronic renal failure and fibrosing mediastinitis.

The Myriad Presentations of Sickle Cell Disease-Related Pulmonary Hypertension by Drs. Prohaska and Machado is a comprehensive review of the most common hemolytic anemia that fall in Group 5 PH: sickle cell disease. The authors offer an insight and guidance into the pathogenesis, diagnosis, prognosis and treatment of this complex group of patients.

In their article Metabolic Disorders of Pulmonary Hypertension, Dr. Oliveros and the guest co-editor of this issue Dr. Vaidya offer a deeper dive into the two metabolic diseases: Glycogen storage diseases and Gaucher’s disease. In their paper, they also cover a topic of the complex relationships between PH and thyroid abnormalities.

Sarcoidosis associated pulmonary hypertension (SAPH) was a hot topic during the 6th World Symposium on Pulmonary Hypertension with a discussion centered on whether it should be “housed” in Group 3 rather than Group 5 category. While the supporters of the move made many persuading arguments that in majority of the cases, SAPH occurs in the setting of a significant parenchymal lung disease, at the end, it remained in Group 5, as there are a number of other etiologic processes that can lead to development of PH in this group of patients. Dr. Kristen Alman and authors offer the readers An Interesting Case of Sarcoidosis Associated Pulmonary Hypertension describing one of such situations in the PH grand Rounds Section. The topic of SAPH is further discussed in the roundtable with great insights from Drs. Roxana Sulica, Stacy Mandras, and Bob Baughman, and facilitated by the co-editors of this issue.

We hope that the readers will find this issue thought provoking, educational and practical. It is important for us as a PH community to continue the ongoing discussions regarding this complex agglomerate of distinct conditions. It is our hope that with the increased awareness of Pulmonary Hypertension in general, this often under-recognized and under-appreciated group will be on the forefront of research, as more guidance is needed to help clinicians caring for these complicated patients.

Oksana Shlobin, MD

Medical Director, Pulmonary Hypertension Program

Director of Education, Advanced Lung Disease and Transplant Program

Inova Fairfax Hospital

Falls Church, VA

Anjali Vaidya, MD

Associate Professor of Medicine

Co-Director, Pulmonary Hypertension, Right Heart Failure, and CTEPH Program

Associate Program Director, Cardiology Fellowship

Temple University Lewis Katz School of Medicine

Philadelphia, PA